​
​

Nurix Therapeutics Ownership | Who Owns Nurix Therapeutics?

OverviewForecastRevenueFinancialsChart

Nurix Therapeutics Ownership Summary

Nurix Therapeutics is owned by 118.38% institutional investors, 1.45% insiders. Blackrock is the largest institutional shareholder, holding 12.42% of NRIX shares. ARK Genomic Revolution is the top mutual fund, with 3.28% of its assets in Nurix Therapeutics shares.

NRIX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockNurix Therapeutics118.38%1.45%-19.84%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock6.82M12.42%$142.33M
Redmile group4.42M8.06%$92.32M
Deep track capital, lp3.99M7.27%$83.30M
Baker bros. advisors lp3.88M7.07%$81.02M
Vanguard group3.63M6.60%$75.65M
Wellington management group llp3.20M5.83%$66.82M
Price t rowe associates inc /md/2.84M5.16%$59.17M
State street2.71M4.93%$56.53M
Ark investment management2.32M4.23%$48.49M
T. rowe price investment management2.19M3.99%$45.69M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Redmile group4.42M5.58%$92.32M
Soleus capital management2.06M3.78%$42.91M
Deep track capital, lp3.99M2.49%$83.30M
Affinity asset advisors912.00K2.19%$19.03M
Opaleye management418.93K2.00%$8.74M
Ikarian capital440.50K1.60%$9.19M
Westhill financial advisors283.33K1.43%$5.91M
Parkman healthcare partners474.68K1.33%$9.91M
Stempoint capital lp203.27K1.25%$4.24M
Baker bros. advisors lp3.88M1.04%$81.02M

Top Buyers

HolderShares% AssetsChange
Wellington management group llp3.20M0.01%2.97M
Blackrock6.82M0.00%2.24M
T. rowe price investment management2.19M0.03%2.19M
Driehaus capital management1.28M0.26%1.28M
Vanguard group3.63M0.00%1.04M

Top Sellers

HolderShares% AssetsChange
Bain capital life sciences investors---1.13M
Ra capital management---650.00K
Morgan stanley1.99M0.00%-541.10K
Deutsche bank ag\1.05M0.01%-450.97K
Wasatch advisors lp858.07K0.10%-378.69K

New Positions

HolderShares% AssetsChangeValue
T. rowe price investment management2.19M0.03%2.19M$45.69M
Driehaus capital management1.28M0.26%1.28M$26.78M
Samlyn capital583.49K0.20%583.49K$12.18M
Norges bank507.54K0.00%507.54K$10.59M
Vestal point capital, lp500.00K0.78%500.00K$10.44M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-9.00
Comerica bank-96.00
Macroview investment management-360.00
Mark sheptoff financial planning-400.00
Pacer advisors-781.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202417524.11%64,997,07932.92%1181.49%11260.00%454.65%
Mar 31, 20241416.82%48,899,6246.46%891.25%702.94%4310.26%
Dec 31, 20231320.76%45,933,2032.43%841.24%6823.64%39-23.53%
Sep 30, 20231311.55%44,845,0992.77%821.26%55-9.84%5118.60%
Jun 30, 20231293.20%43,637,6232.73%801.31%61-3.17%4316.22%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
ARK Genomic Revolution2.20M3.28%-95.17K
ARK Genomic Revolution ETF2.10M2.97%6.18K
Vanguard Total Stock Mkt Idx Inv2.04M2.88%-89.69K
iShares Russell 2000 ETF1.64M2.32%-3.70K
T. Rowe Price New Horizons1.45M2.17%-4.58K
US Small-Cap Growth II Equity Comp1.45M2.17%-5.17K
SPDR® S&P Biotech ETF1.03M1.46%11.42K
Pictet-Biotech P USD989.28K1.40%308.79K
Vanguard Institutional Extnd Mkt Idx Tr909.12K1.28%57.35K
Belfius Equities Cure C Cap624.82K0.93%-142.28K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 04, 2024Ring Christine Chief Legal OfficerSell$82.25K
Nov 01, 2024Ring Christine Chief Legal OfficerSell$139.87K
Nov 01, 2024van Houte Hans Chief Financial OfficerSell$86.08K
Oct 30, 2024van Houte Hans Chief Financial OfficerSell$57.55K
Oct 30, 2024Hansen Gwenn Chief Scientific OfficerSell$83.54K

Insider Transactions Trends

DateBuySell
2024 Q4-9
2024 Q3-13
2024 Q2-9
2024 Q1-4
2023 Q4-5

NRIX Ownership FAQ

Who Owns Nurix Therapeutics?

Nurix Therapeutics shareholders are primarily institutional investors at 118.38%, followed by 1.45% insiders and -19.83% retail investors. The average institutional ownership in Nurix Therapeutics's industry, Biotech Stocks , is 44.97%, which Nurix Therapeutics exceeds.

Who owns the most shares of Nurix Therapeutics?

Nurix Therapeutics’s largest shareholders are Blackrock (6.82M shares, 12.42%), Redmile group (4.42M shares, 8.06%), and Deep track capital, lp (3.99M shares, 7.27%). Together, they hold 27.75% of Nurix Therapeutics’s total shares outstanding.

Does Blackrock own Nurix Therapeutics?

Yes, BlackRock owns 12.42% of Nurix Therapeutics, totaling 6.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 142.33M$. In the last quarter, BlackRock increased its holdings by 2.24M shares, a 48.90% change.

Who is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested?

Redmile group is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested, with 5.58% of its assets in 4.42M Nurix Therapeutics shares, valued at 92.32M$.

Who is the top mutual fund holder of Nurix Therapeutics shares?

ARK Genomic Revolution is the top mutual fund holder of Nurix Therapeutics shares, with 3.28% of its total shares outstanding invested in 2.2M Nurix Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools